They must demonstrate the ability to manufacture and distribute the drug or the FDA just won't approve it. It's as simple as that.
Jon said at the AGM the 2591 commercial product is being made now and will be ready for phase 3 trials. He also said the gap between phase 2 and 3 trials will be much shorter than for Daybue and proceedings will start after the terms are determined with the FDA in this quarter's meeting.
In my opinion, Neuren is prepared for any eventuality whether it be your suggestion or a takeover.
Possibly a new direction?, page-26
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.99 |
Change
0.540(2.64%) |
Mkt cap ! $2.682B | |||
| Open | High | Low | Value | Volume |
| $20.56 | $21.55 | $20.54 | $12.48M | 591.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 435 | $20.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.99 | 1001 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |